Table 1.
FDA-Approved oncology drugs with labels that have been revised to include Toxicity predictive markers [43], [44], [46].
| Drug | Year of treatments’ FDA Approval | Predictive Biomarker |
|---|---|---|
| Capecitabine | 1998 | DPYD |
| Cisplatin | 1978 | TPMT poor metabolisers |
| Fluorouracil | 2000 | DPYD |
| Irinotecan | 1996 | UGT1A1 |
| Mercaptopurine | 1953 | TPMT poor metabolisers |
| Nilotinib | 2007 | UGT1A1 |
| Pazopanib | 2009 | UGT1A1 |
| Rasburicase | 2002 | G6PD |
| Sebrafenib | 2018 | G6PB |
| Tamoxifen | 1977 | CYP2D6 poor metabolisers |
| Tamoxifen | 1977 | F5; Factor V Leiden carriers |
| Tamoxifen | 1977 | F2; Prothrombin mutation G20210A |
| Thioguanine | 1966 | TPMT poor metabolisers |
CYP2D6, Cytochrome P450 2D6; DPYD, dihydropyrimidine dehydrogenase; G6PD, glucose-6-phosphate dehydrogenase; F2, coagulation factor II; F5, coagulation factor V; TPMT, thiopurine S-methyltransferase; UGT1A1, UDP glucuronosyltransferase 1 family, polypeptide A1.